Shortening Rare Kidney Disease Trial Timelines by Integrating Imaging & Molecular Biomarkers into Endpoint Frameworks to Generate Earlier Proof-of-Concept Data
- Evaluating Total Kidney Volume (TKV) as the current imaging-based surrogate endpoint for disease progression in ADPKD clinical trials
- Understanding how imaging endpoints correlate with renal function decline and long-term patient outcomes, supporting their role in accelerating clinical development
- Exploring opportunities to combine imaging with molecular biomarkers, including polycystin and emerging biomarkers, to improve endpoint sensitivity
- Addressing the technical and feasibility challenges of complex biomarker assays, such as exosome-based biomarkers, when implementing them in multicenter clinical trials